CGTX COGNITION THERAPEUTICS INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1455365 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY42.9%
TTM EPS YoY66.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-48.6%
ROA-40.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets15.9%
Debt / equity0.00x
Current ratio6.68x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.96x
Accruals ratio-1.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $37.19M | $41.68M | $37.20M | $30.32M | $18.57M |
| SG&A expense | $10.61M | $12.29M | $13.53M | $13.23M | $10.03M |
| Operating income | -$47.80M | -$53.97M | -$50.72M | -$43.55M | -$28.60M |
| Interest expense | — | — | — | — | $895,000 |
| Pretax income | $23.49M | $33.97M | -$25.77M | -$21.38M | -$10.91M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$23.49M | -$33.97M | -$25.79M | -$21.40M | -$11.72M |
| EBITDA | -$47.76M | -$53.86M | -$50.63M | -$43.47M | -$28.50M |
| EPS (basic) | -0.32 | -0.86 | -0.86 | -0.91 | -3.13 |
| EPS (diluted) | -0.32 | -0.86 | -0.86 | -0.91 | -3.13 |
| Weighted avg. shares (diluted) | 72.77M | 39.73M | 30.03M | 23.64M | 5.19M |
| Banking | |||||
| Net interest income | — | — | -$27,000 | -$28,000 | -$893,000 |
| Balance sheet | |||||
| Cash & equivalents | $36.81M | $25.01M | $29.92M | $41.56M | $54.72M |
| Current assets | $47.99M | $29.55M | $34.22M | $47.65M | $58.99M |
| PP&E, net | $93,000 | $181,000 | $284,000 | $233,000 | $145,000 |
| Total assets | $48.39M | $30.23M | $35.16M | $50.42M | $59.14M |
| Current liabilities | $13.92M | $11.14M | $10.17M | $7.79M | $7.86M |
| Total liabilities | $14.12M | $11.48M | $10.69M | $10.18M | $7.86M |
| Shareholders' equity | $34.27M | $18.75M | $24.47M | $40.25M | $51.27M |
| Shares outstanding | 88.90M | 59.85M | 32.17M | 28.99M | 22.23M |
| Cash flow statement | |||||
| Operating cash flow | -$24.59M | -$28.47M | -$16.02M | -$18.53M | -$3.63M |
| Capital expenditure | — | $4,000 | $147,000 | $171,000 | $27,000 |
| Free cash flow | — | -$28.48M | -$16.16M | -$18.70M | -$3.66M |
| Investing cash flow | $9,000 | -$4,000 | -$147,000 | -$171,000 | -$27,000 |
| Financing cash flow | $36.57M | $23.57M | $4.52M | $5.55M | $53.20M |
| Depreciation & amortization | $36,000 | $107,000 | $96,000 | $83,000 | $93,000 |
| Stock-based compensation | $2.09M | $3.75M | $4.35M | $3.57M | $5.18M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.